Fulcrum Therapeutics, Inc.: Revision history

20 August 2022

• curprev 00:0300:03, 20 August 2022 95.149.241.133 talk 1,270 bytes +11 No edit summary undo

12 August 2022

• curprev 22:0622:06, 12 August 2022 109.180.50.163 talk 1,259 bytes +15 No edit summary undo

29 July 2022

• curprev 04:5904:59, 29 July 2022 >Chris 1,244 bytes +1,244 Created page with "Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobi..."